Latest News

Second batch of 3.92m AstraZeneca vaccine doses expected in August ― NPHCDA

Published by

The Executive Secretary, National Primary Health Care Development Agency (NPHCDA), Dr Faisal Shuaib has disclosed that another batch of AstraZeneca vaccine will be delivered to Nigeria by the end of July or early August 2021.

Faisal stated this at a media briefing on Tuesday in Abuja while giving an update on the COVID-19 vaccine exercise.

“We now have information that Nigeria will get 3.92m doses of Oxford/AstraZeneca by end of July or early August”.

“As we receive additional information on the exact dates in August, we will provide an update regarding timelines and details of this”.

Shuaib also disclosed that recent research from Public Health England (PHE) shows that the Indian (Delta) variant B.1.617.2 is 92% susceptible to Oxford/AstraZeneca.

“It is therefore comforting to know that the vaccine used in Nigeria can protect against this variant that caused high morbidity and mortality in India. However, it underscores the need for us to ramp up our vaccination to more Nigerians.”

“As you all are aware, hesitancy towards the second dose is very tied to the continued misinformation and disinformation about COVID-19 and the vaccination program globally and locally.”

“This is especially prevalent on social media. While I commend the patriotism of a multitude of our social media influencers, I must say that I profoundly appreciate the contributions our professional media community has been making towards the progress of the COVID-19 vaccination campaign in Nigeria.”

“Nevertheless, the challenge is upon us to go beyond straight news and do more in educating Nigerians through interpretative stories, promotional exclusives, features and special broadcast programs on the benefits of COVID-19 vaccination.”

“It is important to emphasize the need to be fully protected with the second dose, and the socio-economic and health risks of refusing to be vaccinated.”

Shuaib further reiterated on the recently concluded G7 summit as the World leaders addressed the issue of vaccine inequities supply particularly for developing countries to get the vaccine.

“While we are working with our international partners to confirm the next shipment of vaccines to Nigeria, I wish to speak about the G7 summit that occurred over the weekend.

“The topic of global inequities in the vaccine supply was a significant focus of the G7 meeting.”

“Rightfully so. Leaders of major, rich countries are becoming increasingly aligned with the thinking that the inequities cannot continue, not only because it is a moral failure but because it is strategically unwise for their own efforts to end the COVID-19 pandemic.”

“On the final day of the summit, leaders committed to delivering at least 1 billion coronavirus vaccine doses to the world over the next year.”

“While this will not close the enormous gap that exists today, it is a positive step and we welcome the new focus.”

“Additionally, President Biden announced on the eve of the summit that the US will purchase 500 million doses of the Pfizer-bioNTech vaccine and donate them to low- and middle-income countries through the next year.”

“This pledge is by far the largest yet by one country. These doses will be distributed via Covax. We welcome this announcement and encourage other nations with the means to follow the US’ example so that we, as a global community, can move forward from COVID-19 swiftly.”

“In other positive news, the Mastercard Foundation has pledged to donate $1.3 billion for vaccines in Africa over the next three years in partnership with the Africa Centers for Disease Control and Prevention.”

“This is one of the largest corporate donations of the pandemic, globally. The goals of this cooperation are to strengthen the Africa CDC’s capacity, support local vaccine manufacturing, procure vaccines for at least 50 million people, and help deliver shots to millions more.

“We applaud Mastercard’s decision and hope it will serve as an impetus for other corporations to follow with similar efforts.

The Country Representative of World Health Organisation Walter Kazadi Molumbo Kazadi Mulombo warned Nigerians to be careful of the looming 3rd wave of the COVID-19 pandemic, as many African lives are at risk.

“Wearing a face mask and taking preventive measures will prevent the spread of COVID-19.”

He says Nigerians should expect another round of COVAX vaccine.

YOU SHOULD NOT MISS THESE HEADLINES FROM NIGERIAN TRIBUNE

We Have Not Had Water Supply In Months ― Abeokuta Residents

In spite of the huge investment in the water sector by the government and international organisations, water scarcity has grown to become a perennial nightmare for residents of Abeokuta, the Ogun State capital.  Second batch of 3.92m AstraZeneca vaccine doses expected in August  ;  Second batch of 3.92m AstraZeneca vaccine doses expected in August  ;  Second batch of 3.92m AstraZeneca vaccine doses expected in August  ;  Second batch of 3.92m AstraZeneca vaccine doses expected in August.

Recent Posts

BREAKING: ASUU elects new leaders as Osodeke’s tenure ends

The Academic Staff Union of Universities (ASUU) has elected new national

25 minutes ago

NIN: Nigerians to pay N28,574 for date of birth correction — NIMC

Nigerians who wish to correct their NIN date of birth on the National Identification Number…

28 minutes ago

Leadership failure causes insurgency, corruption in Nigeria — UNIFEMGA

" failure of leadership in Nigeria in the past has caused the nation a lot…

39 minutes ago

Niger state generally safe, says Commissioner

Niger State Commissioner for Homeland Security, Brig. Gen. Bello Abdullahi (Rtd), has assured that Niger…

55 minutes ago

How wildlife hazards cripple operations at Nigeria’s airports

In 2021, Air Peace alone suffered 14 bird strikes, which affected its engines, while in…

1 hour ago

Kaduna: Nestle, others unveil initiative to support 25,000 smallholder farmers

In a bold step towards building a climate-resilient agricultural sector, AGRA, Nestlé Nigeria, and TechnoServe…

1 hour ago

Welcome

Install

This website uses cookies.